News

The initial analysis of the first 46 patients of a 200 patient Phase-II, multi-center open-label clinical study, NHL-003, showed encouraging results that are consistent with those of the

A 53% response rate was demonstrated at the 90mg dose with a median time to response of less than two months. The overall results indicate a 36% response

The Good Health Company’s programs are designed to empower individuals to take control of their health and are said to be highly complementary to the Focused Health Solutions

Under terms of the agreement, Volcano will pay $25 million in cash at closing, which is expected to occur by the end of the year. In addition, Volcano

Under the agreement, ChemDiv will be initiating a high-throughput screen for small molecule inhibitors of tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech with access to ChemDiv’s expertise in

The data presented showed that seven out of ten patients achieved responses including three complete remissions (30%), four partial remissions (40%), one patient with stable disease, and two

The Nexfin monitors are said to provide provide precise and easy to use continuous non-invasive blood pressure and cardiac output monitoring. Bmeye received CE market approval earlier this

In these pre-clinical studies, two monoclonal antibodies in development depleted targeted B-cells, without significantly affecting the non-targeted B-cells. Results for both studies showed that the number of target

Although enrollment was completed at the end of September 2007, three patients with stable disease continue to receive CTCE-9908 therapy. One patient with small bowel carcinoma is now